Brief: Frequency Therapeutics Announces First Subject Dosed In FX-322 Phase 2B Acquired Sensorineural Hearing Loss (Snhl) Study
21/10/2021 12:34
Oct 21 (Reuters) - Frequency Therapeutics Inc FREQ.O :
* FREQUENCY THERAPEUTICS ANNOUNCES FIRST SUBJECT DOSED IN
FX-322
PHASE 2B ACQUIRED SENSORINEURAL HEARING LOSS (SNHL) STUDY AND
FDA AGREEMENT ON SPEECH PERCEPTION AS PRIMARY ENDPOINT
Source text for Eikon: ID:nBw2sthSGa
Further company coverage: FREQ.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Korro Bio
See all newsBrief: Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121
Brief: Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Korro Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Korro Bio, Inc. expected to post a loss of $1.43 a share - Earnings Preview